Abstract
Paraneoplastic disorders of the central nervous system (CNS) define the compromise of central nervous system diffuse or focally and it is due to an immune response of humoral type or cellular type without either metastasis or direct extension of the tumor. Its incidence is low.
The pathogenesis of paraneoplastic syndromes of the CNS result from immune responses to intracellular antigens mediated mainly by T cells and responses mainly by antibodies to antigens expressed by tumors on cell membranes.
The non paraneoplastic neurologic syndromes and syndromes without a subjacent CNS tumor are two important entities for differential diagnosis, in which there is mediation by antibodies against synaptic proteins and surface cellular proteins. These share similar clinical characteristics with paraneoplastic disorders of CNS. They affect children and young adult and are susceptible to immunotherapy depending on the immunologic mechanism involved.
Paraneoplastic disorders of the central nervous system may precede the tumor presentation. The onconeural antibodies facilitate limit a differential spectrum and lead to an early diagnosis and treatment.
The objective of this review article is sought to the Paraneoplastic disorders of the central nervous system characteristics and the immunologic mechanisms that identify them, to define the antibodies best studied and present a diagnostic and a treatment plans.
References
SCARAVILLI F AN SF, GROVES M, THOM M. The neuropathology of paraneoplastic syndromes. Brain Pathol 1999; 9: 251-260.
GRAUS F, DELATTRE JY, ANTOINE JC, DALMAU J, GIOMETTO B, GRISOLD W, ET AL. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004; 75: 1135-1140.
POSNER JB. Paraneoplastic syndromes. Curr Opin Neurol 1997; 10: 471-476.
BATALLER L, DALMAU J. Paraneoplastic neurologic syndromes. Neurol Clin 2003; 21: 221-247.
ROSENFELD MR, DALMAU J. The clinical spectrum and pathogenesis of paraneoplastic disorders of the central nervous system. Hematol Oncol Clin North Am. 2001; 15: 1109-1128.
DALMAU J, BATALLER L. Clinical and immunological diversity of limbic encephalitis: a model for paraneoplastic neurologic disorders. Hematol Oncol Clin North Am. 2006; 20: 1319-1335.
DIDELOTA A, HONNORAT J. Update on para-neoplastic neurological syndromes. Current Opinion in Oncology 2009; 21: 566-572.
DALMAU J, POSNER JB. Paraneoplastic syndromes affecting the nervous system. Semin Oncol. 1997; 24: 318-328.
ROSENFELD MR, DALMAU J. Update on para-neoplastic and autoimmune disorders of the central nervous system. Seminars in neurology 2010; 30: 320-331.
GIOMETTO B, SCARAVILLI F. Paraneoplastic syndromes. Brain Pathol 1999; 9: 247-250.
DIETRICH P Y, DUTOIT V, TRAN THANG NN, WALKER PR. T-cell immunotherapy for malignant glioma: toward a combined approach. Current Opinion in Oncology 2010; 22: 604-610.
DALMAU J, GULTEKIN HS, POSNER JB. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol 1999; 9: 275-284.
AVERBUCH HL, REMLER B. Opsoclonus. Semin Neurol 1996; 16: 21-26.
GIOMETTO B, TARALOTO B, GRAUS F. Autoimmunity in paraneoplastic neurological syndromes. Brain Pathol 1999; 9: 261-273.
DARNELL RB, POSNER JB. Paraneoplastic syndromes affecting the nervous system. Semin Oncol 2006; 33: 270-298.
ESPANDAR L, O'BRIEN S, THIRKILL C, LUBECKI LA, ESMAELI B. Successful treatment of cancer-associated retinopathy with alemtuzumab. J Neurooncol 2007; 83: 295-302.
BATCHELOR TT, PLATTEN M, HOCHBERG FH. Immunoadsorption therapy for paraneoplastic syndromes. J Neurooncol 1998; 40: 131-136.
YANG YW, TSAI CH, CHANG FC, LU MK, CHIU PY. Reversible paraneoplastic limbic encephalitis caused by a benign ovarian teratoma: report of a case and review of literatures. J Neurooncol. 2006; 80: 309312.
BENKE T, WAGNER M, PALLUA AK, MUIGG A, STOCKHAMMER G. Long-term cognitive and MRI findings in a patient with paraneoplastic limbic encephalitis. J Neurooncol 2004; 66: 217-224.
DARNELL RB. Paraneoplastic neurologic disorders: windows into neuronal function and tumor immunity. Arch Neurol 2004; 61: 30-32.
DAS A, HOCHBERG FH, MCNELIS S. A review of the therapy of paraneoplastic neurologic syndromes. J Neurooncol 1999; 41: 181-194.
BORONAT A, SABATER L, SAIZ A. GABA-B receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 2011; 76: 795-800.
ADAMS C, MCKEON A, SILBER MH, KUMAR R. NARCOLEPSY, REM Sleep Behavior Disorder, and Supranuclear Gaze Palsy Associated With Ma1 and Ma2 Antibodies and Tonsillar Carcinoma. Arch Neuro. 2011; 68: 521-524.
OHTA K, KIKUCHI T, YOSHIDA N. Slowly progressive non-neoplastic autoimmune-like retinopathy. Graefes Arch Clin Exp Ophthalmol 2011; 249: 155-158.
PRUITT AA. Immune mediated encephalopathies with an emphasis on paraneoplastic encephalopa-thies. Semin Neurol2011; 31: 158-168.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.